396 Suarez PG Floyd K Portocarrero J et al Feasibility and cost effectiveness

396 suarez pg floyd k portocarrero j et al

This preview shows page 47 - 48 out of 49 pages.

396. Suarez PG, Floyd K, Portocarrero J, et al. Feasibility and cost-effectiveness of standardised second-line drug treatment for chronic tuberculosis patients: a na- tional cohort study in Peru. Lancet 2002 ; 359:1980 9. 397. Weis SE, Slocum PC, Blais FX, et al. The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. N Engl J Med 1994 ; 330:1179 84. 398. Jindani A, Nunn AJ, Enarson DA. Two 8-month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: international multicentre randomised trial. Lancet 2004 ; 364:1244 51. 399. Kritski AL, Rodrigues de Jesus LS, Andrade MK, et al. Retreatment tuberculosis cases. Factors associated with drug resistance and adverse outcomes. Chest 1997 ; 111:1162 7. 400. Heldal E, Arnadottir T, Cruz JR, Tardencilla A, Chacon L. Low failure rate in standardised retreatment of tuberculosis in Nicaragua: patient category, drug resistance and survival of chronic patients. Int J Tuberc Lung Dis 2001 ; 5:129 36. 401. Chavez Pachas AM, Blank R, Smith Fawzi MC, Bayona J, Becerra MC, Mitnick CD. Identifying early treatment failure on category I therapy for pulmonary tu- berculosis in Lima Ciudad, Peru. Int J Tuberc Lung Dis 2004 ; 8:52 8. 402. Yoshiyama T, Yanai H, Rhiengtong D, et al. Development of acquired drug resis- tance in recurrent tuberculosis patients with various previous treatment out- comes. Int J Tuberc Lung Dis 2004 ; 8:31 8. 403. Boyles TH, Hughes J, Cox V, Burton R, Meintjes G, Mendelson M. False-positive Xpert(R) MTB/RIF assays in previously treated patients: need for caution in in- terpreting results. Int J Tuberc Lung Dis 2014 ; 18:876 8. 404. Falzon D, Jaramillo E, Schunemann HJ, et al. WHO guidelines for the program- matic management of drug-resistant tuberculosis: 2011 update. Eur Respir J 2011 ; 38:516 28. 405. Bifani PJ, Plikaytis BB, Kapur V, et al. Origin and interstate spread of a New York City multidrug-resistant Mycobacterium tuberculosis clone family. JAMA 1996 ; 275:452 7. 406. Nosocomial transmission of multidrug-resistant tuberculosis among HIV-infected persons Florida and New York, 1988 1991. MMWR Morb Mortal Wkly Rep 1991 ; 40:585 91. 407. Tandon RK, Bansal R, Kapur BM, Shriniwas. A study of malabsorption in intes- tinal tuberculosis: stagnant loop syndrome. Am J Clin Nutr 1980 ; 33:244 50. 408. Berning SE, Huitt GA, Iseman MD, Peloquin CA. Malabsorption of antitubercu- losis medications by a patient with AIDS. N Engl J Med 1992 ; 327:1817 8. 409. Gurumurthy P, Ramachandran G, Hemanth Kumar AK, et al. Malabsorption of rifampin and isoniazid in HIV-infected patients with and without tuberculosis. Clin Infect Dis 2004 ; 38:280 3. 410. Bento J, Duarte R, Brito MC, et al. Malabsorption of antimycobacterial drugs as a cause of treatment failure in tuberculosis. BMJ Case Rep 2010 ; 2010. 411. Burman WJ, Stone BL, Reves RR, et al. The incidence of false-positive cultures for Mycobacterium tuberculosis . Am J Respir Crit Care Med 1997 ; 155:321 6.
Image of page 47
Image of page 48

You've reached the end of your free preview.

Want to read all 49 pages?

  • Winter '16

  • Left Quote Icon

    Student Picture

  • Left Quote Icon

    Student Picture

  • Left Quote Icon

    Student Picture

Stuck? We have tutors online 24/7 who can help you get unstuck.
A+ icon
Ask Expert Tutors You can ask You can ask You can ask (will expire )
Answers in as fast as 15 minutes